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Background: The aim of the TRYTON trial was to demonstrate the safety and efficacy of the TRYTON Side Branch (SB) Stent™ compared to a 
provisional stenting strategy in treating native coronary true bifurcation lesions. Nine-month angiographic follow-up (FU) was performed in a pre-
specified cohort of consecutive pts.
methods: The TRYTON trial randomized 704 pts to TRYTON SB Stent™ with main vessel DES vs. provisional SB treatment with main vessel DES. All 
angiograms were assessed by an independent core laboratory. The primary end-point was target vessel failure (TVF) (the composite of cardiac death, 
MI and target vessel [main or SB] revascularization) at 9 months. A secondary powered endpoint was 9-month angiographic % diameter stenosis 
(%DS) in the SB.
results:  Among the 704 (provisional n=349; TRYTON n=355) pts enrolled, true bifurcation by core lab evaluation was present in 319/355 (89.9%) 
and 301/349 (86.2%) respectively. 326 (46.3%) pts were part of the angiographic cohort and had coronary angiogram available at 9 months 
(168/349 [48.1%] provisional and 158/355 [44.5%] TRYTON). The secondary end-point of in-segment DS% of the SB was significantly higher in the 
provisional group compared to TRYTON group (38.6% vs. 31.6%, p=0.002). A non-significant trend toward higher binary restenosis of the SB with the 
provisional approach was shown (26.6% vs. 22.6%, p=0.44). Among pts with restenosis, the most frequent site was the SB ostium (provisional 45/60 
[75%]; TRYTON 29/47 [62%]). No difference in main vessel DS% or binary restenosis was seen between the 2 groups. Post-hoc analysis of 282 pts 
with SB ≥ 2.25 mm showed an increase in the magnitude of angiographic benefit of the TRYTON stent compared to provisional group (DS%; 30.4% 
vs. 40.6%, p=0.004), with extension of this benefit to the primary clinical endpoint (TVF; 11.3% vs. 15.6%, p=0.38, respectively).
conclusions: Dedicated bifurcation TRYTON stent improved 9-month angiographic outcomes of the SB without negatively impacting the main 
vessel. This benefit increased with larger SB, translating in clinically relevant benefit. Complete angiographic comparative results will be available 
and reported at the time of ACC 2014 presentation.
